Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 224

1.

CDK9 Expression Shows Role as a Potential Prognostic Biomarker in Breast Cancer Patients Who Fail to Achieve Pathologic Complete Response after Neoadjuvant Chemotherapy.

Schlafstein AJ, Withers AE, Rudra S, Danelia D, Switchenko JM, Mister D, Harari S, Zhang H, Daddacha W, Ehdaivand S, Li X, Torres MA, Yu DS.

Int J Breast Cancer. 2018 Oct 14;2018:6945129. doi: 10.1155/2018/6945129. eCollection 2018.

2.

Stable Isotope-Resolved Metabolomic Differences between Hormone-Responsive and Triple-Negative Breast Cancer Cell Lines.

Winnike JH, Stewart DA, Pathmasiri WW, McRitchie SL, Sumner SJ.

Int J Breast Cancer. 2018 Sep 30;2018:2063540. doi: 10.1155/2018/2063540. eCollection 2018.

3.

Characteristics and Determinants of Patients Discontinuation of Breast Cancer Follow-Up Care at the Radiation Oncology Department, University College Hospital, Ibadan, Nigeria.

Dairo MD, Adamu DB, Onimode YA, Ntekim A, Ayeni O.

Int J Breast Cancer. 2018 Aug 12;2018:1597964. doi: 10.1155/2018/1597964. eCollection 2018.

4.

Comparative Assessment of Knowledge, Attitudes, and Practice of Breast Self-Examination among Female Secondary and Tertiary School Students in Ghana.

Fondjo LA, Owusu-Afriyie O, Sakyi SA, Wiafe AA, Amankwaa B, Acheampong E, Ephraim RKD, Owiredu WKBA.

Int J Breast Cancer. 2018 Jul 30;2018:7502047. doi: 10.1155/2018/7502047. eCollection 2018.

5.

Practical Consequences Resulting from the Analysis of a 21-Multigene Array in the Interdisciplinary Conference of a Breast Cancer Center.

Voelker HU, Frey L, Strehl A, Weigel M.

Int J Breast Cancer. 2018 Jul 10;2018:2047089. doi: 10.1155/2018/2047089. eCollection 2018.

6.
7.

Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition.

Schedin TB, Borges VF, Shagisultanova E.

Int J Breast Cancer. 2018 Jun 19;2018:7835095. doi: 10.1155/2018/7835095. eCollection 2018. Review.

8.

Concordance between Immunohistochemistry and Microarray Gene Expression Profiling for Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Statuses in Breast Cancer Patients in Lebanon.

Fakhri GB, Akel RS, Khalil MK, Mukherji DA, Boulos FI, Tfayli AH.

Int J Breast Cancer. 2018 May 31;2018:8530318. doi: 10.1155/2018/8530318. eCollection 2018.

9.

Personalizing Radiation Treatment Delivery in the Management of Breast Cancer.

Ahmed KA, Grass GD, Orman AG, Liveringhouse C, Montejo ME, Soliman HH, Han HS, Czerniecki BJ, Torres-Roca JF, Diaz R.

Int J Breast Cancer. 2018 Jun 10;2018:6729802. doi: 10.1155/2018/6729802. eCollection 2018. Review.

10.

The Impact of Locoregional Therapy in Nonmetastatic Inflammatory Breast Cancer: A Population-Based Study.

Muzaffar M, Johnson HM, Vohra NA, Liles D, Wong JH.

Int J Breast Cancer. 2018 Jun 3;2018:6438635. doi: 10.1155/2018/6438635. eCollection 2018.

11.

Precision Medicine for Breast Cancer: The Paths to Truly Individualized Diagnosis and Treatment.

Harris EER.

Int J Breast Cancer. 2018 May 9;2018:4809183. doi: 10.1155/2018/4809183. eCollection 2018. Review.

12.

The Evolution of Radiation Therapy in Metastatic Breast Cancer: From Local Therapy to Systemic Agent.

Jutzy JMS, Lemons JM, Luke JJ, Chmura SJ.

Int J Breast Cancer. 2018 May 16;2018:4786819. doi: 10.1155/2018/4786819. eCollection 2018. Review.

13.

Safety Assessment of Neoadjuvant Pertuzumab Combined with Trastuzumab in Nonmetastatic HER2-Positive Breast Cancer in Postmenopausal Elderly Women of South Asia.

Hussain N, Said ASA, Khan Z.

Int J Breast Cancer. 2018 Apr 19;2018:6106041. doi: 10.1155/2018/6106041. eCollection 2018.

14.

Breast-i Is an Effective and Reliable Adjunct Screening Tool for Detecting Early Tumour Related Angiogenesis of Breast Cancers in Low Resource Sub-Saharan Countries.

Ghartey FN, Watmough D, Debrah S, Morna M, Anyanful A.

Int J Breast Cancer. 2018 Apr 4;2018:2539056. doi: 10.1155/2018/2539056. eCollection 2018.

15.

Postmastectomy Radiation Therapy: Are We Ready to Individualize Radiation?

Everett AS, Boggs DH, De Los Santos JF.

Int J Breast Cancer. 2018 Mar 1;2018:1402824. doi: 10.1155/2018/1402824. eCollection 2018. Review.

16.

Rate of Clinical Complete Response for 1 Year or More in Bone-Metastatic Breast Cancer after Comprehensive Treatments including Autologous Formalin-Fixed Tumor Vaccine.

Kuranishi F, Imaoka Y, Sumi Y, Uemae Y, Yasuda-Kurihara H, Ishihara T, Miyazaki T, Ohno T.

Int J Breast Cancer. 2018 Jan 22;2018:4879406. doi: 10.1155/2018/4879406. eCollection 2018.

17.

The Use of Sentinel Lymph Node Biopsy in BRCA1/2 Mutation Carriers Undergoing Prophylactic Mastectomy: A Retrospective Consecutive Case-Series Study.

Câmara S, Pereira D, André S, Mira B, Vaz F, Oom R, Marques JC, Leal de Faria J, Rodrigues Dos Santos C.

Int J Breast Cancer. 2018 Jan 1;2018:1426369. doi: 10.1155/2018/1426369. eCollection 2018.

18.

Establishing the Role of Stereotactic Ablative Body Radiotherapy in Early-Stage Breast Cancer.

Barry A, Fyles A.

Int J Breast Cancer. 2018 Feb 1;2018:2734820. doi: 10.1155/2018/2734820. eCollection 2018. Review.

19.

Molecular Signatures of Radiation Response in Breast Cancer: Towards Personalized Decision-Making in Radiation Treatment.

Speers C, Pierce LJ.

Int J Breast Cancer. 2017;2017:4279724. doi: 10.1155/2017/4279724. Epub 2017 Nov 26. Review.

20.

The Immunoexpression of Glucocorticoid Receptors in Breast Carcinomas, Lactational Change, and Normal Breast Epithelium and Its Possible Role in Mammary Carcinogenesis.

Alyusuf R, Wazir JF, Brahmi UP, Fakhro AR, Bakhiet M.

Int J Breast Cancer. 2017;2017:1403054. doi: 10.1155/2017/1403054. Epub 2017 Nov 19.

Supplemental Content

Loading ...
Support Center